Intra-Cellular Therapies To Participate At Upcoming Investor Conferences

NEW YORK, Nov. 23, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced it will participate at the following investor conferences in November 2016:
  • 28th Annual Piper Jaffray Healthcare Conference taking place in New York City from November 29-30, 2016. Sharon Mates, Ph.D., Chief Executive Officer and Chairman, will participate in a Fireside Chat, on November 29, 2016 at 4:00 p.m. Eastern Time.
  • Leerink Partners' POLARxPRESS Bus Tour taking place on November 30, 2016 in New York City. Sharon Mates, Ph.D., will present at 1:30 p.m. Eastern Time.

The live webcast from the Piper Jaffray Healthcare Conference can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

About Intra-Cellular Therapies

Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, including Alzheimer's disease, depression and other neuropsychiatric and neurological disorders. ITI-007, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression and agitation associated with dementia, including Alzheimer's disease. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders.
Contact:Juan Sanchez, M.D. Vice President Corporate Communications and Investor Relations of Intra-Cellular Therapies, Inc. Phone:  212-923-3344Burns McClellan, Inc.Lisa Burns Justin Jackson (Media)jjackson@burnsmc.com212-213-0006

Primary Logo

If you liked this article you might like

The January Effect Is on Time This Year

The January Effect Is on Time This Year

DBV Rises On Phase 3 Results for Peanut Allergy Treatment -- Biotech Movers

DBV Rises On Phase 3 Results for Peanut Allergy Treatment -- Biotech Movers

2 Small Biopharmas With Case of 'Hiccups'

2 Small Biopharmas With Case of 'Hiccups'

3 Small Biotech Stocks Insiders Are Buying

3 Small Biotech Stocks Insiders Are Buying

Intra-Cellular Leaps; Schizophrenia Drug Shows Less Side Effects-Biotech Movers

Intra-Cellular Leaps; Schizophrenia Drug Shows Less Side Effects-Biotech Movers